Gastric inhibitory polypeptide hypersecretion in diabetes mellitus: effect of sulfonylurea treatment.

We studied gastric inhibitory peptide (GIP) in response to a mixed meal in both adult-onset diabetics and normal controls. The adult-onset diabetic group was also studied for immunoreactive GIP (IR-GIP), insulin, and glucose with a test meal before and after tolazamide therapy. Mean basal and meal-stimulated IR-GIP concentrations were greater (P less than 0.05) in the adult-onset diabetic group than in normal controls. With treatment, mean fasting glucose significantly decreased (P less than 0.05) from 206 +/- 14 to 162 +/- 11 mg/dl, and postprandial glucose concentrations were reduced (P less than 0.05) between 5-180 min. In contrast, after 1 month of treatment with tolazamide, IR-GIP concentrations were not significantly altered. Further, basal and postmeal serum insulin levels were significantly higher (P less than 0.05) after tolazamide therapy. We conclude that the enteroinsular axis in terms of IR-GIP is overactive in adult-onset diabetics; tolazamide therapy does not appear to effect its meal-stimulated response.

[1]  H. Mekhjian,et al.  Stimulation of gastric inhibitory polypeptide in normal and duodenal ulcer patients. , 1977, Gastroenterology.

[2]  J. Brown,et al.  Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus , 1977, Diabetes.

[3]  H. Mekhjian,et al.  Localization of gastric inhibitory polypeptide release by intestinal glucose perfusion in man. , 1977, Gastroenterology.

[4]  E. Mazzaferri,et al.  Gastric Inhibitory Polypeptide (GIP) in Maturity-onset Diabetes Mellitus , 1976, Diabetes.

[5]  H. Mekhjian,et al.  Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion. , 1976, Gastroenterology.

[6]  E. Mazzaferri,et al.  Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. , 1975, The Journal of clinical endocrinology and metabolism.

[7]  J. Brown,et al.  Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. , 1974, The Journal of clinical endocrinology and metabolism.

[8]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[9]  J. Brown,et al.  A gastric inhibitory polypeptide. II. The complete amino acid sequence. , 1971, Canadian journal of biochemistry.

[10]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.

[11]  R. Unger,et al.  Entero-insular axis. , 1969, Archives of internal medicine.

[12]  J. Brown,et al.  Preparation of highly active enterogastrone. , 1969, Canadian journal of physiology and pharmacology.

[13]  D. Kipnis,et al.  Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. , 1967, The Journal of clinical investigation.

[14]  N. Mcintyre,et al.  Intestinal factors in the control of insulin secretion. , 1965, The Journal of clinical endocrinology and metabolism.

[15]  H. Elrick,et al.  PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. , 1964, The Journal of clinical endocrinology and metabolism.

[16]  J. L. Barre,et al.  STUDIES ON THE PHYSIOLOGY OF SECRETIN , 1930 .